ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI)

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to find out if certain methods can be used to measure the progression of Alzheimer's disease at an early state.
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to evaluate the safety and efficiency of Simvastatin to slow the progression of Alzheimer's by comparing subjects in the study who are randomly given Simvastatin with those also in the study who are instead given placebo. Simvastatin is a FDA approved prescription oral medication used to lower cholesterol levels in the blood and reduces the risk of heart attack, stroke, and death. This is an NIH sponsored trial.

Clin-STAR Database